相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
Takafumi Sato et al.
CLINICAL INFECTIOUS DISEASES (2019)
Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
Patrice Nordmann et al.
CLINICAL INFECTIOUS DISEASES (2019)
The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics
Malcom G. P. Page
CLINICAL INFECTIOUS DISEASES (2019)
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
Yoshinori Yamano
CLINICAL INFECTIOUS DISEASES (2019)
Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance
Roger Echols et al.
CLINICAL INFECTIOUS DISEASES (2019)
Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin
Takayuki Katsube et al.
CLINICAL INFECTIOUS DISEASES (2019)
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Yohei Doi
CLINICAL INFECTIOUS DISEASES (2019)
Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
Toshiaki Aoki et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward molecularly targeted' therapy
Nadim G. El Chakhtoura et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES (2018)
Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis
Amber Martin et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
Carbapenemase-Producing Organisms: A Global Scourge
Robert A. Bonomo et al.
CLINICAL INFECTIOUS DISEASES (2018)
Carbapenem-resistant Enterobacteriaceae in the community: a scoping review
Ana M. Kelly et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa
Bin Cai et al.
Open Forum Infectious Diseases (2017)
Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study
Thomas Howe McConville et al.
PLOS ONE (2017)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2016)
Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
Amabel Lapuebla et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activity of Meropenem Combined with RPX7009, a Novel beta-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City
Amabel Lapuebla et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
10 x '20 Progress-Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
Helen W. Boucher et al.
CLINICAL INFECTIOUS DISEASES (2013)
分享论文
